Categories Uncategorized

Preclinical Research Shows Mothers Can Pass Allergies to Kids

Researchers from Duke-NUS Medical School, KK Women’s and Children’s Hospital and Agency for Science, Technology and Research in Singapore have discovered that mothers can pass their allergies to their offspring while the babies are developing in the womb. This report was published in the “Science” journal last week.

The study was conducted in accordance with the NACLAR guidelines. The research team’s discovery demonstrates that immunoglobulin E, the main antibody in charge of triggering allergic reactions, can enter the fetus by crossing the placenta. Once inside the fetus, the antibody hitches itself onto fetal mast cells as observed in mice. Fetal mast cells are immune cell types that release the chemicals which trigger an allergic reaction, from asthma to runny noses.

The researchers noted that after birth, newborn mice develop allergic reactions to types of allergen that are similar to their mothers. These findings show that the maternal immunoglobulin E (IgE) can cross a human’s placenta in a similar way.

The senior co-author of the study, Dr. Florent Ginhoux, stated that despite the lack of knowledge surrounding mast cells present in a developing fetus, the study discovered that fetal mast cells matured phenotypically in the course of pregnancy and could be sensitized by maternal IgE that crossed the placenta.

Ashley St. John, an associate professor at Duke-NUS and senior co-author of the study, explained that allergies begin very early in life, with infants experiencing allergic responses that are closely connected to their mothers’ allergic response. Scientists could not explain if genetics were behind this, but the study’s findings seem to have captured interest by showing that allergic responses can be passed to the developing fetus from the mother and showing how allergies can endure after birth.

The study’s findings could be used to develop intervention strategies that limit the transfer of allergies, thus helping reduce neonatal allergy occurrences. Today, 10% to 30% of the global population is affected by allergies, and projections show that the number will continue rising. Developing a solution that stops allergies from being passed from a mother to her child may help bring down those numbers over time, according to the researchers.

A senior consultant with the KKH Department of Reproductive Medicine, Professor Jerry Chan says that from a clinical point of view, learning more about IgE placental transfer would be important in helping develop strategies to decrease the chance of transfer of eczema as well as other allergies from mothers to their infants.

The study’s authors now aim to understand how immunoglobulin E hitching onto mast cells in a fetus’s skin adjusts the newborn’s functions and how it may affect skin physiology after the fetus is born.

An interesting entity in the biotech space that you should watch is DarioHealth Corp. (NASDAQ: DRIO). The company focuses on creating digital therapeutics solutions aimed at helping sufferers of chronic conditions to make behavioral adjustments that improve the quality of their lives.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035

The global market for brain tumor treatments is experiencing significant transformation powered by advances in…

3 days ago

New Blood Test Shows Potential in Revolutionizing Early Parkinson’s Detection

A team of researchers has developed a “cost-effective” and simple blood test with the potential…

5 days ago

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…

5 days ago

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…

6 days ago

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…

1 week ago

Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…

1 week ago